NVO's Rybelsus Meets Primary Goal in MACE Study for Diabetes Patients
A late-stage study shows that Novo Nordisk's oral semaglutide, Rybelsus, cuts the risk of MACE by 14% in T2D patients compared to placebo.
Dr. Scot Gottlieb on Novo Nodrisk's oral diabetes drug, future of weight-loss drugs
Former FDA Commissioner Dr. Scot Gottlieb joins 'Squawk Box' to discuss news of Novo Nordisk's oral diabetes drug cutting heart-related risks in patients, state of the weight-loss drugs market, and...
NVO's Alhemo Gets Positive CHMP Opinion in EU for Haemophilia A or B
The CHMP of the regulatory body in the EU adopts a positive opinion recommending the approval of Novo Nordisk's Alhemo for haemophilia A or B with inhibitors.
Novo Nordisk's oral diabetes drug cuts heart-related risks by 14% in study
Novo Nordisk said on Monday an oral version of its drug semaglutide, helped significantly reduce the risk of cardiovascular events in patients in a late-stage study.
Novo Nordisk A/S: Oral semaglutide demonstrates a 14% reduction in risk of major adverse cardiovascular events in adults with type 2 diabetes in th...
Bagsværd, Denmark, 21 October 2024 — Novo Nordisk today announced the headline results from the SOUL cardiovascular outcomes trial. The double-blinded, randomised trial compared oral semaglutide to...
Novo Nordisk A/S: Alhemo® recommended for European approval as first once-daily subcutaneous prophylactic treatment for people living with haemophi...
Bagsværd, Denmark, 18 October 2024 – Novo Nordisk today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, re...
Ozempic, weight loss drugs found to cut substance abuse
Weight loss drugs such as Novo Nordisk (NYSE:NVO) AS' Ozempic have been found to cut alcohol and opioid abuse, according to a new study. Published in the journal Addiction, the study showed the rat...
Wegovy weight loss drug roll out falling short in the UK
Plans to roll out weight loss drug Wegovy through the NHS have fallen short of expectations after the treatment's approval late last year. Just 800 patients had received prescriptions of the drug b...
Wegovy maker Novo Nordisk bets big on talent, AI partnerships in India
Novo Nordisk , whose global profile has risen along with demand for its Wegovy weight-loss drug, is bolstering operations in the world's most populous nation by beefing up senior leadership in Indi...
Novo Nordisk launches new initiative to prevent childhood obesity in disadvantaged urban communities
Bagsværd, Denmark, 8 October 2024 – Novo Nordisk today announced a new global initiative to prevent obesity in children. The Childhood Obesity Prevention Initiative aims to accelerate the preventio...
Novo Nordisk A/S – Share repurchase programme
Bagsværd, Denmark, 7 October 2024 – On 7 August 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Counc...
Novo Nordisk to invest $158 million in insulin plant in Brazil
Danish drugmaker Novo Nordisk will invest 864 million reais ($158.2 million) to revamp a plant in Brazil responsible for pumping out a quarter of its insulin production globally, the firm said on F...
Evotec and Novo Nordisk Enter into Technology Development Partnership to Support Next-Generation Cell Therapies
Novo Nordisk will provide funding for technology development activities at Evotec to support clinical and commercial manufacturing of stem cell-based therapies HAMBURG, GERMANY / ACCESSWIRE / Septe...
Novo Nordisk (NVO) Rises Higher Than Market: Key Facts
Novo Nordisk (NVO) closed at $125.44 in the latest trading session, marking a +1.41% move from the prior day.
Novo Nordisk CEO testifies before Senate on weight loss drug prices
CNBC's Angelica Peebles reports on Novo Nordisk's testimony before the Senate Health, Education, Labor, and Pensions Committee.
Related Companies